NovaDel to Present at Rodman & Renshaw TechVest Conference in New
York October 27
FLEMINGTON, N.J., Oct. 22 /PRNewswire-FirstCall/ -- NovaDel Pharma, Inc. (AMEX:NVD) will provide an update on the company's product portfolio and
clinical development plans for it oral mucosa delivery technology at the Rodman
& Renshaw TechVest 6th Annual Healthcare Conference at New York City's Waldorf
Astoria, October 26-28.
NovaDel's presentation will be led by Chief Executive Officer Gary A. Shangold,
MD, who will present on Wednesday October 27 at 12:15 pm in the Metropolitan
Room.
A webcast of the presentation will be available on the date of the presentation
and will be archived for 90 days. For details go to
http://www.rodmanandrenshaw.com/.
NovaDel Pharma Inc. is a specialty pharmaceutical company engaged in the
development of novel drug delivery systems for prescription and
over-the-counter drugs. The Company's proprietary lingual spray technology
delivery system offers the patient the potential for (i) fast onset of action;
(ii) improved drug safety by reducing the required drug dosage and reducing
side effects; (iii) improved patient convenience and compliance; and (iv)
enhanced dosage reliability. The Company plans to develop such products
independently and through collaborative arrangements with major pharmaceutical
and biotech companies. To find out more about NovaDel Pharma Inc. |(AMEX:NVD),
visit our website at http://www.novadel.com/.
Except for historical information contained herein, this document contains
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. These statements involve known and unknown
risks and uncertainties that may cause the Company's actual results or outcomes
to be materially different from those anticipated and discussed herein
including, but not limited to, the successful completion of its pilot
pharmacokinetic feasibility studies, the ability to develop products
(independently and through collaborative arrangements), the ability to
commercialize and obtain FDA and other regulatory approvals for products under
development and the acceptance in the marketplace for lingual spray products.. Further, the Company operates in industries where securities may be volatile
and may be influenced by regulatory and other factors beyond the Company's
control. Important factors that the Company believes might cause such
differences are discussed in the risk factors detailed in the Company's most
recent Annual Report and Registration Statements, filed with the Securities and
Exchange Commission. In assessing forward-looking statements contained herein,
if any, the reader is urged to carefully read all cautionary statements
contained in such filings.
Barry C. Cohen Thomas Redington
VP New Business & New Product Development 203-222-7399
908.782-3431 x 2160 212 926-1733
NovaDel Pharma Inc. DATASOURCE: NovaDel Pharma Inc.
CONTACT: Barry C. Cohen, VP New Business & New Product Development of NovaDel Pharma Inc., +1-908-782-3431, ext. 2160; or Thomas Redington, +1-203-222-7399, or +1-212-926-1733, , for NovaDel Pharma Inc.
Web site: http://www.rodmanandrenshaw.com/ http://www.novadel.com/
|